Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | CTSS | P25774 | 6/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
| ▸ | ITGAV | P06756 | 1/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108339 | 1.00 | ACE (0.62) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2730038 | 1.00 | ACE (0.62) | ACEITGB3ITGA2BCTSSCTSK | |
| Hydrochloric Acid SCHEMBL27338139 | 0.99 | ACE (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| Hydrochloric Acid SCHEMBL27338140 | 0.99 | ACE (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| Acetic Acid SCHEMBL2729607 | 0.97 | ACE (0.60) | ACEITGB3ITGA2BCTSSCTSK | |
| Acetic Acid SCHEMBL2729608 | 0.97 | ACE (0.60) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL20187263 | 0.89 | CTSS (0.66) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL18228975 | 0.89 | CTSS (0.66) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1009069 | 0.89 | ACE (0.62) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL19575827 | 0.89 | REN (0.54) | ACEITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058821-A | Prodrug designed based on tumor LAT1 transporter and preparation method thereof | 广西中医药大学 | 2025-05-30 | — | — | CN | claimed |
| CN-118420494-B | Hydroxyl radical reactive unnatural amino acid and preparation method and application thereof | 北京大学深圳研究生院 | 2024-11-29 | — | — | CN | claimed |
| CN-116041210-A | Chiral nano material and preparation method thereof | 南京工业大学 | 2023-05-02 | — | — | CN | claimed |
| US-20110076718-A1 | IN VIVO INCORPORATION OF AN UNNATURAL AMINO ACID COMPRISING A 1,2-AMINOTHIOL GROUP | THE SCRIPPS RESEARCH INSTITUTE | 2011-03-31 | — | — | US | claimed |
| WO-2009151491-A9 | IN VIVO INCORPORATION OF AN UNNATURAL AMINO ACID COMPRISING A 1,2-AMINOTHIOL GROUP | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2009151491-A2 | IN VIVO INCORPORATION OF AN UNNATURAL AMINO ACID COMPRISING A 1,2-AMINOTHIOL GROUP | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-17 | — | — | WO | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-30 | — | — | US | disclosed |
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-5565574-A | BIOSYNTHESIS OF SYNTHETIC PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0736035-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0703900-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE DERIVATIVES OR HOMOLOGUES CONTAINING A GUANIDINO OR MODIFIED GUANIDINO GROUP USEFUL FOR THE PREPARATION GnRH OF ANTAGONISTIC PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995015335-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995000474-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE DERIVATIVES OR HOMOLOGUES CONTAINING A GUANIDINO OR MODIFIED GUANIDINO GROUP USEFUL FOR THE PREPARATION GnRH OF ANTAGONISTIC PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5352796-A | Chemical intermediates for gonadotropin-releasing hormone | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0431784-A2 | Methods for treating retroviral infection | ELI LILLY AND COMPANY (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | ACE 4044/4885ITGB3 156/4885ITGA2B 660/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | ACE 1258/4885ITGB3 3299/4885ITGA2B 1042/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | ACE 1944/4885ITGB3 2864/4885ITGA2B 3805/4885 |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | PTMS, PSMG3, PSMB3 | ACE 1510/4885ITGB3 765/4885ITGA2B 3259/4885 |
| US-20110076718-A1 | IN VIVO INCORPORATION OF AN UNNATURAL AMINO ACID COMPRISING A 1,2-AMINOTHIOL GROUP | AARS1, NSUN3, NPEPPS | ACE 1053/4885ITGB3 3369/4885ITGA2B 4511/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | ACE 663/4885ITGB3 4087/4885ITGA2B 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.